Detection of gyrA and gyrB mutations in Clostridium difficile isolates by real-time PCR

Molecular and Cellular Probes

Volumn 24, Issue 2, 2010, Pages 61-67

  Spigaglia, Patrizia ^a   Carattoli, Alessandra ^a   Barbanti, Fabrizio ^a   Mastrantonio, Paola ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

C. difficile; Fluoroquinolone; Mutation; Real time PCR; Resistance

Indexed keywords

CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; FLUORESCENT DYE; GATIFLOXACIN; GENOMIC DNA; LEVOFLOXACIN; MOXIFLOXACIN; NUCLEOTIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ACCURACY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIUM ISOLATE; CLOSTRIDIUM DIFFICILE; CODON; CONTROLLED STUDY; DNA ISOLATION; GENE AMPLIFICATION; HYBRIDIZATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SCREENING; SEQUENCE ANALYSIS; WILD TYPE;

ALLELES; BASE SEQUENCE; CLOSTRIDIUM DIFFICILE; DNA GYRASE; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; GENES, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MUTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, DNA; TRANSITION TEMPERATURE;

CLOSTRIDIUM DIFFICILE;

EID: 76849085631     PISSN: 08908508     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcp.2009.10.002     Document Type: Article

References (20)

1. Kelly C.P., Pothoulakis C., and LaMont J.T. Clostridium difficile colitis. N Engl J Med 330 (1994) 257-262
2. McFarland L.V., Mulligan M.E., Kwok R.Y., and Stamm W.E. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 320 (1989) 204-210
3. Bartlett J.G. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med 1 45 (2006) 758-764
4. Kuijper E.J., Coignard B., Tüll P., on behalf of the ESCMID Study Group for Clostridium difficile (ESGCD), and EU Member States and the European Centre for Disease Prevention and Control (ECDC). Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 12 Suppl. 6 (2006) 2-18
5. Spigaglia P., Barbanti F., Louie T., Barbut F., and Mastrantonio P. Molecular analysis of the gyrA and gyrB quinolone resistance-determining region (QRDR) of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. Antimicrob Agents Chemother 53 (2009) 2463-2468
6. Biller P., Shank B., Lind L., Brennan M., Tkatch L., Killgore G., et al. Moxifloxacin therapy as a risk factor for Clostridium difficile- associated disease during an outbreak: attempts to control a new epidemic strain. Infect Control Hosp Epidemiol 28 (2007) 198-201
7. Muto C.A., Pokrywka M., Shutt K., Mendelsohn A.B., Nouri K., Posey K., et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 26 (2005) 273-280
8. Pepin J., Saheb N., Coulombe M.A., Alary M.F., Corriveau M.P., Authier S., et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 1 (2005) 1254-1260
9. Spigaglia P., Barbanti F., Mastrantonio P., Brazier J.S., Barbut F., Delmée M., et al., European Study Group on Clostridium difficile (ESGCD). Fluoroquinolone resistance in Clostridium difficile isolates from a prospective study of C. difficile infections in Europe. J Med Microbiol 57 (2008) 784-789
10. Dridi L., Tankovic J., Burghoffer B., Barbut F., and Petit J.C. gyrA and gyrB mutations are implicated in cross-resistance to ciprofloxacin and moxifloxacin in Clostridium difficile. Antimicrob Agents Chemother 46 (2002) 3418-3421
11. Drudy D., Kyne L., O'Mahony R., and Fanning S. gyrA mutations in fluoroquinolone-resistant Clostridium difficile PCR-027. Emerg Infect Dis 13 (2007) 504-505
12. Barbut F., Mastrantonio P., Delmée M., Brazier J., Kuijper E., Poxton I., and European Study Group on Clostridium difficile (ESGCD). Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates. Clin Microbiol Infect 13 (2007) 1048-1057
13. Ackermann G., Degner A., Cohen S.H., Silva J., and Rodloff A.C. Prevalence and association of macrolide-lincosamide-streptogramin B (MLS(b)) resistance with resistance to moxifloxacin in Clostridium difficile. J Antimicrob Chemother 51 (2003) 599-603
14. Ruiz J. Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J Antimicrob Chemother 51 (2003) 1109-1117
15. Drudy D., Quinn T., O'Mahony R., Kyne L., O'Gaora P., and Fanning S. High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile. J Antimicrob Chemother 58 (2006) 1264-1267
16. Dionisi A.M., Luzzi I., and Carattoli A. Identification of ciprofloxacin-resistant Campylobacter jejuni and analysis of the gyrA gene by the LightCycler mutation assay. Mol Cell Probes 18 (2004) 255-261
17. Carattoli A., Dionisi A., and Luzzi I. Use of a LightCycler gyrA mutation assay for identification of ciprofloxacin-resistant Campylobacter coli. FEMS Microbiol Lett 214 (2002) 87-93
18. Li Z., Yokoi S., Kawamura Y., Maeda S., Ezaki T., and Deguchi T. Rapid detection of quinolone resistance-associated gyrA mutations in Neisseria gonorrhoeae with a LightCycler. J Infect Chemother 8 (2002) 145-150
19. Ackermann G., Tang Y.J., Kueper R., Heisig P., Rodloff A.C., Silva Jr. J., et al. Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA. Antimicrob Agents Chemother 45 (2001) 2348-2353
20. Clinical and Laboratory Standards Institute (CLSI). Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard M11-A7. 7th ed. (2007), CLSI, Wayne, PA